Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broa...
